Contribute Try STAT+ Today

WASHINGTON — It has all the makings of a bombastic drug pricing debate: a highly anticipated drug, widespread press attention, a huge potential patient population, and a price higher than even some of the highest Wall Street estimates.

But when Biogen announced Monday it would charge $56,000 for an annual course of its just-approved Alzheimer’s treatment, the activists who are normally eager to criticize pharma and its pricing strategies were largely silent. So, too, were progressives on Capitol Hill, many of whom have decried high drug prices as a key campaign issue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If it’s as useful as Aricept, the Country has been sold a real lemon. For now, what is needed in Dementia is a nutricuetical type placebo with questionable to no efficacy. Think B12. At least that wouldn’t break the bank.

Comments are closed.